![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries announced that it has signed a new three-year agreement with Boston IVF, a pioneer in reproductive healthcare and innovative research and one of the world’s most experienced fertility treatment providers.
Utilizing Cryoport’s end-to-end supply chain solutions, Boston IVF will now have the ability to integrate its regional and satellite labs across Massachusetts, New Hampshire, Maine, Rhode Island, New York and Indiana, along with its partner sites in Delaware, Ohio, Idaho, Utah and North Carolina. Cryoport’s platform will improve the overall efficiency of Boston IVF’s reproductive material shipments and ensure significant risk mitigation for patients and families entrusting Boston IVF with their care.
“Boston IVF is a widely recognized leader for reproductive medicine, having supported more than 150,000 babies born since 1986 while achieving some of the highest IVF success rates in the country,” said Jerrell Shelton, CEO of Cryoport. “As we seek to provide more patients with peace of mind that their reproductive materials are being handled safely and securely, we’re proud to partner with a team that is equally committed to delivering the best outcomes and experiences for their patients.”
“Inside our clinics, our physicians are among the best in treating infertility and have affiliations with the Beth Israel Deaconess Medical Center and Harvard Medical School,” said David Stern, CEO of Boston IVF. “We’re always looking for ways to ensure exceptional patient care from start to finish in each fertility journey, and this includes the vital logistical component outside of the clinic. Cryoport’s cutting-edge technology and nonstop monitoring simplify the entire supply chain process by ensuring that patients’ reproductive materials are safe every step of the way.”
